Illumina (NASDAQ:ILMN) Stock Rating Cut to Equal Weight at Stephens

Illumina (NASDAQ:ILMN) was downgraded by investment analysts at Stephens from an “overweight” rating to an “equal weight” rating in a research report issued on Friday, MarketBeat Ratings reports. They presently have a $275.00 price objective on the life sciences company’s stock. Stephens‘s price target would indicate a potential upside of 2.07% from the company’s current price.

Several other equities analysts have also commented on the stock. Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a report on Sunday, October 11th. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $215.00 price target on shares of Illumina in a report on Friday, July 31st. Stifel Nicolaus boosted their price objective on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Deutsche Bank Aktiengesellschaft downgraded shares of Illumina to a “hold” rating in a research note on Wednesday, August 5th. Finally, Zacks Research downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 1st. Ten analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $234.41.

Illumina Stock Up 0.0%

Shares of NASDAQ:ILMN traded up $0.02 on Friday, reaching $269.42. The company had a trading volume of 1,262,784 shares, compared to its average volume of 2,685,421. Illumina has a twelve month low of $94.00 and a twelve month high of $309.35. The stock has a market capitalization of $40.68 billion, a P/E ratio of 50.26, a P/E/G ratio of 3.82 and a beta of 1.41. The stock has a 50-day moving average price of $242.35 and a 200 day moving average price of $191.10. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%. The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the business posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities analysts expect that Illumina will post 5.36 EPS for the current year.

Insider Buying and Selling

In related news, Director Keith Meister sold 119,501 shares of the company’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the completion of the sale, the director directly owned 770,350 shares of the company’s stock, valued at approximately $168,244,440. This represents a 13.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Christensen Wedel sold 1,033 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total transaction of $197,840.16. Following the sale, the senior vice president owned 14,023 shares of the company’s stock, valued at $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 2,061,850 shares of company stock worth $436,479,102. 2.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Hilton Head Capital Partners LLC bought a new stake in Illumina in the 3rd quarter valued at about $82,000. Leeward Financial Partners LLC purchased a new stake in Illumina in the 3rd quarter worth approximately $4,410,000. Sigma Planning Corp boosted its holdings in Illumina by 91.1% during the 3rd quarter. Sigma Planning Corp now owns 6,980 shares of the life sciences company’s stock valued at $1,910,000 after acquiring an additional 3,327 shares during the period. Signaturefd LLC increased its position in Illumina by 8.4% during the 3rd quarter. Signaturefd LLC now owns 5,897 shares of the life sciences company’s stock valued at $1,614,000 after buying an additional 457 shares in the last quarter. Finally, Evergreen Capital Management LLC raised its stake in shares of Illumina by 0.5% in the third quarter. Evergreen Capital Management LLC now owns 9,474 shares of the life sciences company’s stock worth $2,593,000 after buying an additional 50 shares during the period. Institutional investors own 89.42% of the company’s stock.

Illumina News Summary

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s upcoming quarterly report could benefit from strong clinical demand, NovaSeq X adoption, new instrument placements, and consumables growth. Analysts also expect year-over-year earnings growth and see potential for an earnings beat, although research-market weakness remains a concern. ILMN Q3 Earnings Preview: Strong Clinical Demand May Lift Performance
• Positive Sentiment: The company launched three early-access capabilities for its BioInsight Platform—Workflow Orchestrator, DRAGEN Ultra with dnaAI, and Learning Cohorts. The tools expand Illumina’s AI-driven variant prioritization, sequencing analysis, and genomic-data workflow offerings, potentially increasing the strategic importance of software and data services. How Investors May Respond To Illumina BioInsight AI Rollout
• Neutral Sentiment: Illumina is expected to report quarterly results next week. The event is a major near-term catalyst, with investor attention likely centered on clinical demand, NovaSeq X placements, consumables revenue, and management’s outlook. Illumina Expected to Release Quarterly Earnings on Thursday
• Neutral Sentiment: The consensus price target was raised 19.65% to $250.77, signaling improved analyst expectations, but that target remains below Illumina’s recent trading level and may limit upside if not revised further. Illumina Consensus Price Target Increased
• Negative Sentiment: Stephens downgraded Illumina to Equal Weight, reducing a potential source of buying pressure and reflecting a more cautious view of the stock’s risk-reward profile. Stephens Downgrades Illumina to Equal Weight
• Negative Sentiment: Illumina recently fell alongside Twist Bioscience and other AI- and genomics-related stocks in a broad technology selloff, indicating that sector sentiment—not company-specific news—has also been driving volatility. Twist Bioscience and Illumina Slide as AI and Genomics Stocks Sell Off

Illumina Company Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.